Breaking boundaries in MS research. Sorrel Bickley Research Communications Manager

Similar documents
A look into the future - International Progressive MS Alliance. Dr Dhia Chandraratna Head of Research, MSIF

National MS Society Information Sourcebook

Clinical trials for brain tumours

Cladribine. Spirella Building, Letchworth, SG6 4ET reg charity no

Brain Tumour Australia Information FACT SHEET 22 Clinical Trials: Questions and Answers

Stem cells and motor neurone disease

The Importance of Participating in Clinical Trials in Alzheimer s Disease. Amanda G. Smith, M.D. Medical Director USF Health Byrd Alzheimer Institute

Research collaboration with Q Therapeutics and its founder Dr. Mahendra Rao. REPROCELL Inc., 2017

Medical Practitioner. Medical Practitioner. Medical Practitioner. Medical Practitioner. Medical Practitioner. Medical Practitioner

Stem cell therapies in MS

Information Pack. Information, Advocacy and Research Officer. Based at. MS Ireland National Office 80 Northumberland Road Dublin 4

Research Strategy Delivering internationally excellent research for a healthy, safe and sustainable society

JOB DESCRIPTION. Network Manager (NHS Clinical Commissioners) (Initially fixed term contract to end of October 2015)

PhysicsAndMathsTutor.com. Question Number. Answer Additional guidance Mark. 1(a) 1. reference to stem cells being {totipotent / pluripotent} ;

Smouldering myeloma. Myeloma Infosheet Series. Other related conditions. Infoline:

The NYSCF Research Institute

Future of Stem Cell Engineering. Jaeseung Jeong, Ph.D Department of Bio and Brain Engineering KAIST

LETTER OF INTENT Early Phase Clinical Trials 2018

JOB DESCRIPTION. Network Manager (NHS Clinical Commissioners) (Initially fixed term contract to end of February 2016)

POSITION DESCRIPTION MS CARE. MS Consultant (PT,OT, SW, CSW, RN) Practice Leader Local Area

The Latest Therapies for MS: Weighing Respective Benefits and Risks

Stem Cell Uses and FDA Regulation

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal

Rain International U.S. Distributor Guide

Multiple Sclerosis Research Program

Medical Topics: Gene Therapy. E. Anne Jackson, FSA MAAA July 30, 2018

Special Issue. Mesoblast Limited

Scientists don t yet fully

Gene Therapy and Ethics: the Patient View. A tool for public dialogue

Stem cell dialogue: key findings, conclusions and recommendations. Dr Darren Bhattachary, Director BMRB

Lesson 7A Specialized Cells, Stem Cells & Cellular Differentiation

Switching focus. Making employment and pay better for people with disabilities - Who is responsible for it?

CLINICAL TRIALS AND MARKET RESEARCH

JOB DESCRIPTION JOB TITLE: STATUS: HOURS: SALARY: HOLIDAY: LOCATION: REPORTS TO: DIRECT REPORTS: KEY INTERNAL RELATIONSHIPS:

Immunotherapy in myeloma

Stem Cells in Life and Disease: Immortality Inside You

BIOLOGIC AND BIOSIMILAR MEDICATIONS

The Wellcome Trust. FundERS rd Sept 2015

Becoming a Next Generation Stem Cell Company

Board members will have the ambition to play a major role in growing participation, increasing sporting opportunities and creating a more physically

Understanding brain diseases from stem cells to clinical trials

Stem Cells: Introduction and Prospects in Regenerative Medicine.

JOB DESCRIPTION. Network and Engagement Manager (NHS Clinical Commissioners) (Fixed term contract to end of August 2016)

INUED DISCONTINUED DISCONTINUED DISCON MAKING THE IMPOSSIBLE POSSIBLE CENTER FOR REGENERATIVE MEDICINE

S.E.A.R.C.H. SM Patient Workbook

B1 Quick Revision Questions. B1 for AQA GCSE examination 2018 onwards

BIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD. crohnsandcolitis.ca

Dear Colleague DL (2017) 25. Everyone Matters: 2020 Workforce Vision Implementation Plan December 2017

Information and resources for African Americans living with multiple myeloma and their caregivers

Gene Therapy for Lung Diseases. Deborah Gill Gene Medicine Research Group Oxford University

Opexa Therapeutics, Inc.

NHS ENGLAND BOARD PAPER

AstraZeneca Code of Ethics Values, Behaviours, and Policies

Introducing MN-166 Multiple Sclerosis. July 9, 2008

Application Pack. Director of Fundraising

STEM CELLS IN NEUROLOGY ISABELLE COCHRANE MERIT

Position Description

STEM CELL ETHICS: THE NEGLECTED ISSUES. Dr. Christie Holland Rev. Dr. Karen Lebacqz

Job Description. Community Fundraising Manager. Head Office, Nene Hall, Peterborough. Grade: 4. Full Time hours/week. Charity Description

To provide management and direction for the Major Donor Fundraising activities across the MS Society

Unified understanding of MS disease is required for drug development. National Multiple Sclerosis Society, 733 Third Avenue, New York, NY USA 2

NETWORKING AND CUREACCELERATOR LIVE!

How Logistics Enables the Healthcare Revolution. Richard Holmes Managing Director of Polar Speed Distribution Ltd, a UPS company

International Progressive Multiple Sclerosis Collaborative : Update on Research Strategy

Challenge Events Manager 12 month Fixed Term Contract

Multiple Sclerosis Treatment Market Research Report - Global Forecast till 2023

(Health and Social Care)

Stem Cell Research: Identifying emerging high priority policy issues

Education Critical to Stem Cell Therapy Pipeline

Media Release. Basel, 14 June 2018

Stem Cell Research From Bench to Bedside

Reolysin. This Horizons Infosheet contains information on Reolysin, an oncolytic virus being investigated for the treatment of myeloma.

MONASH BIOMEDICINE DISCOVERY INSTITUTE. At a Glance. monash.edu/discovery-institute

Learning about Clinical Trials

(Travel within Suffolk will be required) 37.5 hours (Flexible hours incl at least 2 evenings and weekends)

More Effective Treatments for Multiple Myeloma Convention Connection: American Society of Hematology Meeting December 2010 Dan Vogl, M.D.

Overview. FTD Genetics where is it leading us? What comes first or? Family History. AFTD Education Conference and Annual Meeting, White Plains, 2014

Role title Project and Communications Manager Directorate Strategy and Research Location London Accountable to Assistant Director, Research Travel

Business Plan

Translational Research

BEFORE, DURING AND AFTER A STEM CELL TRANSPLANT

The 3Rs: are Human Stem Cells and Organs on Chip alternatives?

First Place Essay. Katie P.

A. TRIAL IDENTIFICATION

Advanced Therapy Medicinal Products and GMP. Ashley Isbel

FDA Perspectives On Viral & Vector Shedding Studies. Daniel Takefman, Ph.D. Chief, Gene Therapy Branch FDA/CBER ICH Workshop: October 31, 2007

Treatment: Nutrition and Medication

Transplantation Society. Transplantation Building Bridges to Excellence. World Wide Transplantation. Outline 9/28/2016

DNA Structure and Replication. Higher Human Biology

THE PATH TO PRECISION MEDICINE IN MULTIPLE MYELOMA. themmrf.org

Long term treatment of multiple sclerosis with interferon-beta may be cost effective Kendrick M, Johnson K I

Unit 1: DNA and the Genome. Sub-Topic (1.4) Cellular Differentiation

Rx EDGE. Patient Aquisition and Patient Adherence Programs. Contents. Pharmacy Networks

Treatment strategies for relapsing and refractory myeloma

CADTH Canadian Drug Expert Committee Recommendation

Partnering with Rare Disease Patient Groups. Namrata Taak R&D External Communications, Rare Diseases

Delivering on the Promise of Precision Medicine

National Horizon Scanning Centre. Cladribine (Movectro) for multiple sclerosis; relapsing-remitting. April 2008

Types of product/intervention

RESEARCH/CLINICAL UPDATE

Transcription:

Breaking boundaries in MS research Sorrel Bickley Research Communications Manager

Disclaimer Research Team are not medical professionals If anyone is worried about the treatments they are taking speak to your healthcare professional

What is MS?

Early on in the condition myelin can repair itself As people age, the body looses its ability to repair myelin No licensed therapies that promote myelin repair

What is progression?

How does the body attack myelin? The immune system 1. Immune cells patrol the body 2. Cells travel to the infection site 3. Immune response happens 4. Infection is cleared (leaves scars) In MS These immune cells mistakenly attack myelin They leave scars where they have attacked

The immune system and MS Blood-brain barrier

Our Research Programme

Where were we 20 years ago? No disease modifying treatments 1 gene linked with MS Little progress in understanding environmental factors Symptom relief research was limited

Where are we today? 11 licensed disease modifying treatments 110 genes linked to MS Increased understanding of risk factors Positive phase 2 secondary progressive MS clinical trial New symptom management treatments developed (e.g. FACETS)

Investment in research Largest UK charitable funder of MS research: 4-5 million per year Over 148 million invested since 1956 Supporting 62 projects, totalling over 15 million Fund top UK researchers carrying out world-class research

Our research strategy Focus on progression Understanding myelin repair Impact of MS Symptom management New ways of supporting research (collaborations) Continue to involve people with MS

Top 10 research priorities Partnership James Lind Alliance, MS Society, MS Therapy Centres, ABN, UKMSSNA Top 10 research priorities shared by people affected by MS and health care professionals 1084 questions submitted 669 voted to get to a top 30 Top 10 decided at a workshop www.mssociety.org.uk/jla

Top 10 research priorities 1. Which treatments are effective to slow, stop or reverse the accumulation of disability associated with MS? 2. How can MS be prevented? 3. Which treatments are effective for fatigue in people with MS? www.mssociety.org.uk/jla

How will we beat MS? Cure Cause Symptom relief Services Biomedical research Care and services research Improved diagnosis, treatments, services and support

Biomedical research

Cambridge & Edinburgh Exploring how remyelination can be encouraged Developing potential treatments and testing them in the laboratory Recent remyelination breakthroughs Development of small myelin repair therapy clinical trial

MS Society Tissue Bank Funded by MS Society since 1998 World class facility Over 280 projects so far Supports treatment development Understanding causes

Queen Square MRI Unit We have supported MRI research since 1982 New 3-Tesla scanner purchased in 2009 (more detailed images) Support progression research and clinical trials

Causes of MS We don t know the cause of MS A mix of genetic and environmental factors Genes and family history Vitamin D Viruses Smoking Obesity +

Vitamin D MS more common away from the equator Several studies suggest vitamin D deficiency plays a role in risk of developing MS but not clear how We don t know: 1. if vitamin D will help prevent or treat MS 2. what dosage is needed 3. what dose is safe 4. if supplements work If you re worried about your vitamin D levels, speak to your doctor

Genes and MS No single gene that causes MS Studies published in 2011 and 2013 found over 110 genes linked with MS Many of these genes play a role in influencing the immune system

Stem cells what are they? Unspecialised cells - make more of their own - make many type of cells Types - embryonic - adult - induced pluripotent

How could stem cells help in MS? As treatments 1. Provide neuroprotection - prevent further damage to nerves - myelin repair 2. Repair nerve fibers For research

Stem cells what s next? Funding partnership with UKSCF to fund new projects including phase 2 clinical trial Mesenchymal stem cell trial results - small phase 2-10 people with SPMS - tolerated - visual improvements

Care and services research

The MS Register World leading MS register Revolutionising our understanding of MS Supports (1) Research (2) Service development (3) Campaigning www.ukmsregister.org

MS Register results www.ukmsregister.org

Botox for Bladder Botox injections shown to be a safe and effective treatment for overactive bladder Early clinical trial funded by MS Society Effective for around 10 months Now licensed in the UK

Fatigue management FACETS: group based Cognitive Behavioural Therapy energy effectiveness (lifestyle decisions and ways of working) rolled out across the UK

Adjusting to MS Nurse led, telephone based therapy Positive results in clinical trial - reduces distress - improves quality of life - lasts for 12 months Part of MS healthcare package? Professor Rona Moss-Morris

Exercise and MS Pilates with wheelchairs Accessible form of exercise Improvements to quality of life and health Wii TM develop for pwms use at home small clinical trial EXIMS practical exercise programme Tailored to individual 12-week clinical trial Improvements to QoL

Progressive MS

What is progression?

Neuroprotection Neuroprotective therapies urgently needed Aimed at preventing damage to nerves Could slow or halt progression Two trials to protect nerves: amiloride trial ( 377,000) phenytoin trial ( 250,000)

Partnership between many organisations and MS researchers (MS Societies from UK, USA, Italy, Canada, Australia and MSIF) First partnership of its kind in MS Coordinate progressive MS research on an international scale Fund research difficult for an individual MS Society to fund Speed up the development of treatments for progressive MS http://www.progressivemsalliance.org/

Dr Alan Thompson (Chair of the Alliance Scientific Steering Committee) I don t think it is an understatement to say that this is the most ambitious project in the history of progressive MS. 22 projects funded in 2014 Bigger, more ambitious projects getting underway next year

Simvastatin cholesterol lowering drug phase 2 trial 140 people with SPMS slow brain atrophy and disability progression First positive progressive MS trial in recent years

MS SMART Groundbreaking clinical trial Three different drugs against a dummy tablet 440 people with SPMS 10-15 sites in England and Scotland www.ms-smart.org Jointly funded by the MRC and the MS Society

So how long does it take? 17 years from an idea to a successful treatment! 3 years: from an idea to a project actually starting! EARLY RESEARCH: TESTING THE IDEA Clinical trials take at least 7 years to complete CLINICAL TRIAL: STAGES 1-3 LICENCING & MONITORING Researcher has an idea and decides how to test it Researcher applies for funding Researcher applies for ethical approval Staff recruited to project. Project starts Results are reported: Good - project moves on Not Good - go back to start Phase I clinical trial Phase II clinical trial Phase III clinical trial If trials are successful, researcher applies for licence Long term safety and monitoring 6 months 12 months 6 months 6 12 months 3 6 years 12 months 1 3 years 2 3 years 12 months Many years

Get involved in research Clinical trials: www.clinicaltrials.gov MS Society website research pages www.mssociety.org.uk/ms-research/getinvolved-research 1. Be in a study 2. MS Register 3. MS Society Tissue Bank 4. Research Network

Find out more Research Matters www.mssociety.org.uk Research Blog MS Society you tube channel research@mssociety.org.uk

Questions?

Our strategy 2015 to 2019

Our strategic goals 1. Effective treatments 2. Responsive care and support 3. Preventing MS 4. Quality information 5. A strong community, independent lives 6. Supporting families and carers 7. Greater certainty about the future

Our strategic approach Working alongside people affected by MS Working collaboratively Prioritisation Impact Inclusion UK-wide, national, and local approaches